Deregulation of the cytoplasmic tyrosine kinase cSrc in the absence of a truncating mutation at codon 531 in human bladder carcinoma

Biochemical and Biophysical Research Communications

Volumn 273, Issue 2, 2000, Pages 425-430

  Benistant C ^a   Chapuis, H ^b   Mottet, N ^b   Noletti, J ^c   Crapez, E ^c   Bali, J P ^d   Roche, S ^a  

^a Centre National de la Recherche Scientifique   (France)

^b NÎMES UNIVERSITY HOSPITAL   (France)

^c CENTRE VAL D AURELLE   (France)

^d UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE P60;

AFFINITY CHROMATOGRAPHY; ARTICLE; BLADDER CARCINOGENESIS; CARBOXY TERMINAL SEQUENCE; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME REGULATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; PRIORITY JOURNAL; TRANSITIONAL CELL CARCINOMA;

EID: 0343081484     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2000.2948     Document Type: Article

References (33)

1. Rezvani A., Mollie A., Doyon F., Sancho-Garnier H. Atlas de la mortalité par le cancer en France. 1997.
2. Cairns P., Shaw M. E., Knowles M. A. Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. Cancer Res. 53:1993;1230-1232.
3. Tsai Y. C., Nichols P. W., Hiti A. L., Williams Z., Skinner D. G., Jones P. A. Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. Cancer Res. 50:1990;44-47.
4. Sidransky D., Von Eschenbach A., Tsai Y. C., Jones P., Summerhayes I., Marshall F., Paul M., Green P., Hamilton S. R., Frost P. Identification of p53 gene mutations in bladder cancers and urine samples. Science. 252:1991;706-709.
5. Cairns P., Proctor A. J., Knowles M. A. Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma. Oncogene. 6:1991;2305-2309.
6. Spruck C. H. 3rd, Ohneseit P. F., Gonzalez-Zulueta M., Esrig D., Miyao N., Tsai Y. C., Lerner S. P., Schmutte C., Yang A. S., Cote R. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 54:1994;784-788.
7. Onodera T., Hashimoto Y., Yagihashi S. c-myc, c-erbB-1 and c-erbB-2 expressions in urothelial carcinoma. Pathol. Int. 47:1997;209-216.
8. Boyer B., Roche S., Denoyelle M., Thiery J. P. Src and Ras are involved in separate pathways in epithelial cell scattering. EMBO J. 16:1997;5904-5913.
9. Roche S., Koegl M., Barone M. V., Roussel M. F., Courtneidge S. A. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol. Cell. Biol. 15:1995;1102-1109.
10. Roche S., Fumagalli S., Courtneidge S. A. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science. 269:1995;1567-1569.
11. Bolen J. B., Veillette A., Schwartz A. M., DeSeau V., Rosen N. Activation of pp60c-src protein kinase activity in human colon carcinoma. Proc. Natl. Acad. Sci. USA. 84:1987;2251-2255.
12. Cartwright C. A., Meisler A. I., Eckhart W. Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis. Proc. Natl. Acad. Sci. USA. 87:1990;558-562.
13. Loganzo F. Jr., Dosik J. S., Zhao Y., Vidal M. J., Nanus D. M., Sudol M., Albino A. P. Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene. 8:1993;2637-2644.
14. Cartwright C. A., Coad C. A., Egbert B. M. Elevated c-Src tyrosine kinase activity in premalignant epithelia of ulcerative colitis. J. Clin. Invest. 93:1994;509-515.
15. Luttrell D. K., Lee A., Lansing T. J., Crosby R. M., Jung K. D., Willard D., Luther M., Rodriguez M., Berman J., Gilmer T. M. Involvement of pp60c-src with two major signaling pathways in human breast cancer. Proc. Natl. Acad. Sci. USA. 91:1994;83-87.
16. Chedin M., Filhol O., Duminy C., Bolla M., Benistant C., Roche S., Chambaz E. M., Cochet C. Characterization of two different cytoplasmic protein tyrosine kinases from human breast cancer. Carcinogenesis. 18:1997;1463-1472.
17. Mukhopadhyay D., Tsiokas L., Zhou X. M., Foster D., Brugge J. S., Sukhatme V. P. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature. 375:1995;577-581.
18. Irby R. B., Mao W., Coppola D., Kang J., Loubeau J. M., Trudeau W., Karl R., Fujita D. J., Jove R., Yeatman T. J. Activating SRC mutation in a subset of advanced human colon cancers. Nat. Genet. 21:1999;187-190.
19. Roche S., Dhand R., Waterfield M. D., Courtneidge S. A. The catalytic subunit of phosphatidylinositol 3-kinase is a substrate for the activated platelet-derived growth factor receptor, but not for middle-T antigen-pp60c-src complexes. Biochem. J. 301:1994;703-711.
20. Koegl M., Kypta R. M., Bergman M., Alitalo K., Courtneidge S. A. Rapid and efficient purification of Src homology 2 domain-containing proteins: Fyn, Csk and phosphatidylinositol 3-kinase p85. Biochem. J. 302:1994;737-744.
21. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
22. Nakamura K., Chijiiwa Y., Nawata H. Augmented expression of LCK message directed from the downstream promoter in human colorectal cancer specimens. Eur. J. Cancer. 32A:1996;1401-1407.
23. Williams J. C., Wierenga R. K., Saraste M. Insights into Src kinase functions: Structural comparisons. Trends Biochem. Sci. 23:1998;179-184.
24. Ilic D., Furuta Y., Kanazawa S., Takeda N., Sobue K., Nakatsuji N., Nomura S., Fujimoto J., Okada M., Yamamoto T. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice. Nature. 377:1995;539-544.
25. Fanning P., Bulovas K., Saini K. S., Libertino J. A., Joyce A. D., Summerhayes I. C. Elevated expression of pp60c-src in low grade human bladder carcinoma. Cancer Res. 52:1992;1457-1462.
26. Ponniah S., Wang D. Z., Lim K. L., Pallen C. J. Targeted disruption of the tyrosine phosphatase PTPalpha leads to constitutive downregulation of the kinases Src and Fyn. Curr. Biol. 9:1999;535-538.
27. Su J., Muranjan M., Sap J. Receptor protein tyrosine phosphatase alpha activates Src-family kinases and controls integrin-mediated responses in fibroblasts. Curr. Biol. 9:1999;505-511.
28. Egan C., Pang A., Durda D., Cheng H. C., Wang J. H., Fujita D. J. Activation of Src in human breast tumor cell lines: Elevated levels of phosphotyrosine phosphatase activity that preferentially recognizes the Src carboxy terminal negative regulatory tyrosine 530. Oncogene. 18:1999;1227-1237.
29. Johnson P. J., Coussens P. M., Danko A. V., Shalloway D. Overexpressed pp60c-src can induce focus formation without complete transformation of NIH 3T3 cells. Mol. Cell. Biol. 5:1985;1073-1083.
30. Yatsula B. A., Plachy J., Mikhailik A., David-Pfeuty T., Lecoq O., Yatsula V., Geryk J., Svoboda J., Calothy G., Dezelee P. Phenotypic changes induced by wild type and variant c-src genes carrying C-terminal sequence alterations. Oncogene. 13:1996;2717-2725.
31. Okada M., Nada S., Yamanashi Y., Yamamoto T., Nakagawa H. CSK: A protein-tyrosine kinase involved in regulation of src family kinases. J. Biol. Chem. 266:1991;24249-24252.
32. Thomas J. W., Ellis B., Boerner R. J., Knight W. B., White G. C. 2nd, Schaller M. D. SH2- and SH3-mediated interactions between focal adhesion kinase and Src. J. Biol. Chem. 273:1998;577-583.
33. Wright D. D., Sefton B. M., Kamps M. P. Oncogenic activation of the Lck protein accompanies translocation of the LCK gene in the human HSB2 T-cell leukemia. Mol. Cell. Biol. 14:1994;2429-2437.